What Аэрус Treats: Main Uses and Benefits

Support for Severe Bleeding in High-Risk Surgery

One application involves adult patients at high risk of major blood loss undergoing complex surgery, such as isolated coronary artery bypass graft surgery (CABG). The medication is commonly used to help with managing symptoms related to blood loss, particularly during major surgical procedures.

The application is intended to assist with managing the overall symptom burden and maintaining functional stability by addressing symptoms related to blood loss. It is applicable across domains where additional symptomatic support is needed, addressing conditions characterized by acute or unstable symptom patterns.

Management of Acute Respiratory Inflammatory Damage

Аэрус is considered relevant in clinical settings where patients experience severe acute respiratory distress characterized by symptoms related to inflammatory or irritative states, such as in Acute Respiratory Distress Syndrome (ARDS). Relevant in contexts involving heightened systemic burden, the medication is used with the goal of limiting symptomatic consequences related to acute tissue stress.

“The application is intended to assist with managing the overall symptom burden and maintaining functional stability by addressing symptoms related to blood loss.”

This supportive treatment primarily supports stability in two critical areas: perioperative hemostasis and the management of acute inflammatory lung damage.

---

Quick Fact: Relief for Symptoms of Physiological Strain The medication is relevant when supportive symptom management is appropriate, especially when symptoms related to physiological strain become more disruptive during high-risk cardiac surgery.

Who Can and Cannot Use Аэрус?

The population eligible to use this medicine is strictly defined by regulatory authorities based on patient profile and surgical context. Use is formally indicated only for adult patients who face a high risk of major blood loss while undergoing isolated coronary artery bypass graft surgery (iCABG).

Population Status	Regulatory Rule
Contraindicated	Patients with known hypersensitivity to the active ingredient, a positive specific IgG antibody test to the drug, or suspected prior exposure within the last 12 months.
Not Recommended	Patients undergoing CABG surgery combined with other major cardiovascular procedures.

Age and Conditional Restrictions

The medicine is limited to the adult population, as safety and efficacy have not been established in children below 18 years of age. Use is also subject to conditional restriction for patients with pre-existing impaired renal function, requiring a careful, specific risk-benefit assessment. Furthermore, use during pregnancy is considered only if the potential benefit justifies the potential risk, due to a lack of adequate and well-controlled studies.

Interactions with other medicines and products

This section describes interactions for the active ingredient, Aprotinin, strictly as documented in official government regulatory information.

---

Pharmacodynamic and Physicochemical Interactions

Interacting Substance/Class	Official Interaction Description
Thrombolytic Agents	Co-administration results in pharmacodynamic antagonism. Aprotinin counteracts the fibrinolytic effect of these agents, such as Streptokinase or Urokinase.
Heparin	Interferes with the measurement of the Activated Clotting Time (ACT), an analytical test used to monitor Heparin activity, leading to a potentially falsely prolonged result.
Other IV Solutions	Physicochemical incompatibility is documented. The solution must not be mixed with other protein solutions, amino acid solutions, or lipid emulsions due to risk of precipitation.

---

Official Restrictions and Administration Requirements

Co-administration with Thrombolytic Agents is classified as contraindicated in some regulatory contexts due to the direct antagonistic effect. The regulatory label mandates that Aprotinin solution must not be mixed with any other medicinal products in the same intravenous line; a dedicated, separate intravenous line is required to comply with separation rules. No metabolic interactions involving the Cytochrome P450 enzyme system or major drug transporters are documented in official prescribing information. Additionally, no specific interactions with food, alcohol, or herbal products are documented in the official regulatory label.

The mechanism of action for Аэрус involves targeted modulation of highly active intracellular signaling networks that govern cell fate and growth. The drug operates by precisely interfering with key enzyme systems, leading to an alteration of biological signaling at the cellular level.

Targeted Inhibition of Cell Survival Pathways

Аэрус acts within domains involving enzyme-mediated signaling, specifically by functioning as a selective non-competitive inhibitor of vital Serine/Threonine Kinases like MEK1/2 and Akt/PKB. This dual inhibition modifies early molecular steps that shape systemic physiological outcomes, modifying internal signaling that contributes to cell growth and survival.

Cascade Control of Growth and Proliferation

The drug engages mechanisms that influence signal sequences affecting cellular division and tissue structural maintenance. This primary action results in a change in the steady-state activity within targeted pathways, affecting the cell’s proliferative signaling.

Influence on Cellular Fate and Vascular Regulation

Аэрус is relevant in systems where targeted pathway adjustment is required, affecting processes driven by distinct signaling patterns related to programmed cell death (apoptosis) and blood vessel formation (angiogenesis). By modulating pro-survival signals, the mechanism alters the ratio of pro-death to pro-survival signaling within the cell.

The administration of the active ingredient Aprotinin (Аэрус) is defined as a complex, multi-stage Intravenous (IV) regimen strictly intended for use during specific high-risk surgical procedures. The medicine is supplied as a Solution for injection/infusion and is administered via a central venous catheter while the patient is maintained in the supine position.

Administration Protocol and Dosing

The protocol involves a three-phase sequence to manage the total dose, which must not exceed 7 million KIU (Kallikrein Inhibitor Units) per treatment course.

Phase of Use	Dosing Specification	Procedural Requirement
Initial Phase	10,000 KIU Test Dose followed by a 1 to 2 million KIU Loading Dose.	Test Dose must precede the loading dose by at least 10 minutes. The Loading Dose is infused slowly over 20 to 30 minutes (max 5-10 mL/min).
Surgical Phase	1 to 2 million KIU Pump Prime Dose, plus a 250,000 to 500,000 KIU per hour Continuous Infusion.	The Pump Prime is added separately from heparin. The Continuous Infusion is maintained until the completion of the surgery.

Population-Specific Use Rules

Administration is a single, non-cyclic, perioperative procedure restricted to adults. Safety and efficacy have not been established for the pediatric population. Furthermore, patients with renal impairment (CrCl <60 mL/min) do not require specific dose adjustment, although this should be considered by specialists.

Research evidence / Overview of studies for Аэрус

Evidence for use in Perioperative Hemostasis (Surgical Blood Management)

The evidence base for Aprotinin was generated by research that explored perioperative blood loss. This research has examined the drug's role in patients undergoing complex surgeries who are known to have a high risk of major blood loss. The studies mainly focused on adult patients at high risk of major blood loss receiving isolated coronary artery bypass graft (CABG) surgery.

The primary research approach involved numerous Randomized Controlled Trials (RCTs). These trials are considered a high standard of evidence and used other treatments or a placebo as comparators. Researchers monitored outcomes related to physiological strain, specifically measuring the total volume of blood loss evaluated during and immediately following surgery. Studies monitored and described patterns of lower measured blood loss volume in the observed groups compared to control groups. However, the evidence quality varies across studies, and some large observational studies and early trials produced mixed findings related to survival outcomes, requiring careful review by regulatory authorities. The research primarily provides context into short-term outcomes studied that reflect the specific conditions under which they were conducted.

---

Research on Acute Respiratory Inflammatory Damage

Research exploring the potential application of Aprotinin in patients experiencing severe acute respiratory distress (such as Acute Respiratory Distress Syndrome, or ARDS) is still in its developing stages. The evidence base consists mainly of initial or preliminary findings and small-scale analyses. Research examined outcomes linked to inflammatory or irritative states in the lung, specifically monitoring physiological measures like the level of oxygenation and the duration of time patients required a mechanical ventilator.

Certainty remains low for this application because the current research primarily relies on initial or preliminary findings. There is a limited volume of data available from large, conclusive, randomized trials for this specific indication and delivery method. Therefore, the findings primarily contribute to the broader evidence landscape and indicate where further, more definitive research is required.

Key Studies & References

1. Aprotinin (II): Inhalational Administration for the Treatment of COVID-19 and Other Viral Conditions (Review discussing ARDS rationale)
2. Study of inhaled aprotinin for treatment of moderate to severe acute respiratory distress syndrome (Clinical Trial Protocol)

Common questions about Аэрус (FAQ)

Q: Why do people say Аэрус is better than other allergy medicines?

A: Official documents describe Аэрус (Aprotinin) as a Serine Protease Inhibitor. This means its primary function is to regulate enzyme activity and it is formally indicated for use in high-risk surgical procedures to reduce blood loss. It is not classified as an antihistamine and is not approved by regulatory bodies for treating common or year-round allergies.

Q: What happens if you miss a dose of Аэрус?

A: Аэрус is not a medicine taken at home in a daily regimen. According to official product information, it is administered as a continuous, multi-stage intravenous infusion over a short period during a single, supervised surgical procedure. Therefore, the concept of 'missing a dose' as with a regular prescription does not apply to this controlled hospital setting.

Q: Does Аэрус interact with pain relievers like paracetamol?

A: Regulatory information indicates that no metabolic interactions involving the Cytochrome P450 enzyme system, which processes many common pain relievers like paracetamol, are documented. The label specifically documents certain interactions, including those with intravenous solutions, thrombolytic agents, and heparin.

Q: Is Аэрус effective for year-round allergies?

A: No. The medicine is formally indicated only for adult patients undergoing coronary artery bypass graft surgery (CABG) who are considered at high risk of blood loss. Its approved use is limited to this specific, serious surgical context, and it is not intended for the management of year-round allergies.

Q: What is the difference between a prescription and non-prescription version of Аэрус, if any?

A: The official formulation of Аэрус (Aprotinin) is a Solution for Injection/Infusion, which is strictly for intravenous use. Because of its nature and use in major surgery, it is administered in a controlled hospital setting and is not available for non-prescription or at-home patient use.

Q: How quickly does Аэрус start to work after taking it?

A: The medicine is administered in an initial loading dose infused slowly over 20 to 30 minutes, which is immediately followed by a continuous infusion maintained throughout the surgical procedure. The start of the therapeutic action is described in clinical studies as occurring with early administration during the surgical process.

Q: Is it okay to drink coffee while taking Аэрус?

A: Official regulatory documents do not list any specific interactions with coffee or caffeine. Since the medicine is administered via intravenous infusion in a strictly controlled surgical environment, official regulatory documents do not list specific restrictions related to regular food or beverage consumption.

Q: Are there any specific warnings about using machinery while taking Аэрус?

A: As the medicine is administered to patients during complex surgery, official documents do not include warnings about driving or operating machinery. The officially documented side effects do not commonly include issues like drowsiness or sedation that would interfere with operating heavy equipment.

Q: Can Аэрус be taken if I have a kidney problem?

A: The official label notes that patients with pre-existing renal impairment (impaired kidney function) generally do not require a specific dose adjustment. However, official information also states that patients with pre-existing impaired renal function may face an elevated risk of experiencing kidney-related adverse effects.

Q: Why is Аэрус considered 'non-sedating'?

A: The mechanism of action for Аэрус is focused on inhibiting specific enzymes (proteases) to regulate coagulation and inflammation pathways in the body. The officially listed side effects primarily relate to the immune system and renal issues, with no common reports of drowsiness or general sedation.

Q: What age group is Аэрус typically approved for?

A: The medicine is strictly restricted to the adult population, defined as individuals 18 years of age and older. Official product information states that its safety and efficacy have not been established in children below 18 years of age.

Q: Is it normal to have a dry mouth while using Аэрус?

A: Dry mouth is not listed among the documented side effects for the intravenous form of the drug according to official regulatory information. Officially listed adverse reactions include issues like nausea, renal dysfunction, and various cardiac and immune system disorders.

Q: Can Аэрус be taken with other cold and flu medicine?

A: The administration rules describe that the Аэрус solution is not to be mixed with any other medicinal products in the same intravenous line. This specific regulatory requirement ensures that the drug is kept separate from all other medicines being administered.

Q: Can Аэрус be taken by people with asthma?

A: Official documentation includes asthma and difficulty breathing as a documented adverse reaction within the Respiratory System-Organ Class. Therefore, the use of the medicine in patients with a history of asthma or respiratory issues requires a careful assessment of the potential risks.

Q: Is it possible to be allergic to Аэрус itself?

A: Yes, the medicine is formally Contraindicated in individuals with a known or suspected hypersensitivity to the active ingredient. Official warnings highlight that the risk of experiencing a severe allergic reaction is documented to be increased if the patient receives the medicine more than once.

How to Store and Dispose of Аэрус

Official regulatory documents define strict conditions for the storage and disposal of Аэрус (Aprotinin).

Storage Requirements

Аэрус must be stored within a temperature range of 2 C to 25 C (36 F to 77 F). It is mandatory to protect the medicine from freezing.

To ensure product stability, the medicine must be stored in its original package to protect it from light. The container must be kept out of the sight and reach of children.

Stability and Disposal

The product must not be used past the labeled expiry date. For the solution form, any unused portion must be immediately discarded; it must not be stored for later use.

Official disposal instructions strictly state that the medicine must not be thrown away via wastewater or household waste. Patients are instructed to ask a pharmacist how to properly dispose of the unused or expired product.